Capture, Protect, Prevent
NoriZite™ Nasal Spray coats the nasal cavity and creates a fast, long-lasting barrier against airborne virus particles.
Common human coronaviruses and cold and flu usually spread from an infected person to others through the air by coughing and sneezing.{1}
Developed by experts at the Healthcare Technologies Institute at the University of Birmingham, NoriZite Nasal Spray acts as an invisible shield in the nose, to help reduce the risk of virus particles infecting cells.
The nose is the main entry site of SARS-CoV-2 and plays a central role in the transmission, modulation, and progression of COVID-19.{2}
Carry out your daily activity with an added layer of protection and peace of mind.
Product Information
Available in 20ml
NoriZite Nasal Spray is a medical device with a unique formulation designed to target one of the main sites of infection: the nose.
Science has proven that the nasal passage plays a critical role in our first defence against harmful bacteria and viruses entering the body.
NoriZite Nasal Spray is intended to be used prior to situations where the exposure to viruses is likely to be high and there is an increased likelihood of person-to-person transmission.
This medical device is not a treatment, it is a gel-like barrier designed to trap viruses in the nose and prevent them from replicating and entering the body. The two main ingredients are iota-carrageenan and gellan gum.
Featured Products
-
NoriZite Nasal Spray - 20ml
![]()
- Regular price
- R 299.00
- Sale price
- R 299.00
- Regular price
-
- Unit price
- per
Sold out
Scientifically Proven
The spray has been formulated at the Healthcare Technologies Institute at the University of Birmingham.
Laboratory studies at the University of Birmingham have shown that the NoriZite formulation can prevent contraction and transmission of SARS-CoV-2 in cell culture. The research confirmed the complete inhibition of SARS-CoV-2 infection up to 48h when exposed to the carrageenan/gellan blend.{3g}
Follow-up lab studies at the University of Birmingham have indicated that NoriZite™ is also effective against Alpha, Delta and Omicron variants of SARS-CoV-2 in cell culture. Birmingham Biotech plans to test the efficacy of the product against other SARS-CoV-2 variants, as well as other viruses causing common cold and flu including rhinovirus, influenza viruses, and respiratory syncytial virus (RSV), in the future.
References
- Centers for Disease Control and Prevention. 2020. Common Human Coronaviruses.
- Gallo, O. et al., The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection. Mucosal Immunology 2021, 14, 305–316.
- a) Grassauer, A. et al., Iota-Carrageenan is a potent inhibitor of rhinovirus infection. Virology Journal 2008, 5, 107; b) Leibbrandt, A. et al., Iota-Carrageenan Is a Potent Inhibitor of Influenza A Virus Infection. PLoS ONE 2010, 5, e14320; c) Morokutti-Kurz, M. et al., Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro. PLOS ONE 2021, 16, e0237480; d) Song, S. et al., Inhibitory activities of marine sulfated polysaccharides against SARS-CoV-2. Food & Function 2020, 11, 7415; e) Schütz, D. et al., Carrageenan-containing over-the-counter nasal and oral sprays inhibit SARS-CoV-2 infection of airway epithelial cultures. American Journal of Physiology-Lung Cellular and Molecular Physiology 2021, 320, L750; f) Fröba, M. et al., Iota-Carrageenan Inhibits Replication of SARS-CoV-2 and the Respective Variants of Concern Alpha, Beta, Gamma and Delta. International Journal of Molecular Sciences 2021, 22, 13202; g) Moakes, R. et al. Formulation of a Composite Nasal Spray Enabling Enhanced Surface Coverage and Prophylaxis of SARS-COV-2. Advanced Materials. 2021.33(26), 2008304.
- Wang, CC. et al., Airborne transmission of respiratory viruses. Science. 2021; 373eabd9149.
- Centers for Disease Control and Prevention. 2021. Scientific Brief: SARS-CoV-2 Transmission.
- a) Eccles, R. et al., Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: A randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold. Respiratory Research 2010, 11; b) Fazekas, T. et al., Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold. BMC Complementary and Alternative Medicine 2012, 12, 147; c) Ludwig, M. et al., Efficacy of a Carrageenan nasal spray in patients with common cold: A randomized controlled trial. Respiratory Research 2013, 14; d) Koenighofer, M. et al., Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials. Multidisciplinary Respiratory Medicine 2014, 9, 57; e) Eccles, R. et al., Efficacy and safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold in adults: The ICICC trial. Respiratory Research 2015, 16, 121.
- Nasal Swab samples analysed by high performance liquid chromatography (HPLC) coupled UV-Vis spectroscopy - study conducted by LabWide Solutions HK Ltd.
Brands
Location
Visit Us
809 Rubenstein Drive, Moreleta Park, Pretoria, 0181
Mon - Fri, 08:30am - 4pm